Entera Bio Ltd
NASDAQ:ENTX
Entera Bio Ltd
Selling, General & Administrative
Entera Bio Ltd
Selling, General & Administrative Peer Comparison
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Entera Bio Ltd
NASDAQ:ENTX
|
Selling, General & Administrative
-$4.4m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Selling, General & Administrative
-$6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
Selling, General & Administrative
-$29.5m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-11%
|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Selling, General & Administrative
-$31.2m
|
CAGR 3-Years
-88%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Selling, General & Administrative
-$93.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Selling, General & Administrative
-₪13.3m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-14%
|
See Also
What is Entera Bio Ltd's Selling, General & Administrative?
Selling, General & Administrative
-4.4m
USD
Based on the financial report for Dec 31, 2023, Entera Bio Ltd's Selling, General & Administrative amounts to -4.4m USD.
What is Entera Bio Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-9%
Over the last year, the Selling, General & Administrative growth was 39%. The average annual Selling, General & Administrative growth rates for Entera Bio Ltd have been 3% over the past three years , -9% over the past five years .